ArticleBrain tumor pathology2026
CDKN2A deletion associated with poor prognosis in patients with TERT promoter wild-type, IDH wild-type glioblastoma.
Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
TERT promoter (TERTp) mutations are among the most frequent molecular alterations in isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM), yet the molecular profiles and prognostic implications associated with TERTp status remain incompletely characterized. This study aimed to delineate differences in molecular characteristics and prognostic factors according to TERTp status in histologically defined, IDH wild-type GBM. Clinical and molecular characteristics and survival outcomes were retrospectively assessed according to TERTp status. Among 112 patients, 70 (62.5%) harbored TERTp mutations. Molecular alteration profiles differed substantially according to TERTp status. Among the molecular alterations evaluated, cyclin-dependent kinase inhibitor 2 A (CDKN2A) deletion, encompassing homozygous and hemizygous deletions, was significantly associated with shorter overall survival (OS) in the overall cohort (P = 0.016). In TERTp-stratified multivariable analyses, CDKN2A deletion remained independently associated with shorter OS in the TERTp wild-type subgroup (hazard ratio, 5.0; 95% confidence interval, 1.8-13.7; P = 0.002), whereas no significant association was detected in the TERTp-mutant subgroup. Formal interaction analyses demonstrated significant interactions between TERTp status and CDKN2A deletion for both progression-free survival (P = 0.004) and OS (P = 0.005). TERTp status was associated with distinct molecular alteration profiles in histologically defined, IDH wild-type GBM. The prognostic relevance of CDKN2A deletion may vary according to TERTp status, particularly for OS.
Indexed as
Identifiers
42859331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.